We postulated that EphA2 signaling maintains neoplastic features of NSCLC cells and tested this hypothesis by treating HCC827 cells with EphA2-Fc, a recombinant peptide containing the EphA2 extracellular domain fused to the Fc fragment of IgG, which prevents the interaction of ephrin A ligands with endogenous EphA, effectively blocking EphA activation [26]. The gene discussed is EPHA2; the disease is non-small cell lung carcinoma.